Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Nov 23;10:5605–5619. doi: 10.2147/OTT.S149200

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2017 Xie et al. This work is published and licensed by Dove Medical Press Limited

The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.

PMC Copyright notice

RKIP reduction enhances Shh–Gli1 signaling and increases CD133 expression in NSCLC cell lines.

Notes: (A) Representative Western blot results show the expression levels of RKIP, Smo, Gli1 and CD133 in A/RKIP-KD, SK/RKIP-KD and the corresponding control cell lines A-EV and SK-EV; the results when these cell lines were treated with N-shh and cyclopamine are also shown. β-actin was used as a loading control. (B) Histograms show the relative expression levels of RKIP, Smo, Gli1 and CD133 in the cells by grayscale analysis. Data are presented as the mean ± SD. ⁺P<0.05 vs cells transfected with empty vectors; *P<0.05 vs cells transfected with empty vectors; ^#P<0.05 vs cells with RKIP knockdown. All experiments were performed in triplicate.

Abbreviations: EV, empty vector; KD, knockdown; NSCLC, non-small-cell lung cancer; RKIP, Raf kinase inhibitor protein; A-EV, A549 cells transfected with empty vector; A/RKIP-KD, A549 cells transfected with RKIP-knockdown vector; SK-EV, SK-MES-1 cells transfected with empty vector; SK/RKIP-KD, SK-MES-1 cells transfected with RKIP-knockdown vector.

RKIP reduction enhances Shh–Gli1 signaling and increases CD133 expression in NSCLC cell lines.

Notes: (A) Representative Western blot results show the expression levels of RKIP, Smo, Gli1 and CD133 in A/RKIP-KD, SK/RKIP-KD and the corresponding control cell lines A-EV and SK-EV; the results when these cell lines were treated with N-shh and cyclopamine are also shown. β-actin was used as a loading control. (B) Histograms show the relative expression levels of RKIP, Smo, Gli1 and CD133 in the cells by grayscale analysis. Data are presented as the mean ± SD. ⁺P<0.05 vs cells transfected with empty vectors; *P<0.05 vs cells transfected with empty vectors; ^#P<0.05 vs cells with RKIP knockdown. All experiments were performed in triplicate.

Abbreviations: EV, empty vector; KD, knockdown; NSCLC, non-small-cell lung cancer; RKIP, Raf kinase inhibitor protein; A-EV, A549 cells transfected with empty vector; A/RKIP-KD, A549 cells transfected with RKIP-knockdown vector; SK-EV, SK-MES-1 cells transfected with empty vector; SK/RKIP-KD, SK-MES-1 cells transfected with RKIP-knockdown vector.